natgillin/translations-raw huggingface dataset:
Bleggul til let gul, hexagonal, bikonveks, filmovertrukken tablet. 
Pale to light yellow, hexagonal, biconvex, film-coated tablet.
Symptomer på malignt neuroleptika syndrom (MNS) kan forekomme under behandling med Tasmar. 
NMS (Neuroleptic Malignant Syndrome): Symptoms of Neuroleptic Malignant Syndrome (NMS) may occur during Tasmar treatment.
Når Tasmar tages sammen med levodopa (som levodopa/benserazid eller levodopa/carbidopa) betyder det, at symptomerne på Parkinsons sygdom mindskes. 
This means when it is taken together with levodopa (as levodopa/benserazide or levodopa/carbidopa) you should have an improvement in the symptoms of your Parkinson's disease.
Tag altid Tasmar nøjagtigt efter lægens eller apotekspersonalets anvisninger. 
Always take Tasmar exactly as your doctor has told you.
Tabletkernen: Calciumhydrogenphosphat (vandfrit), mikrokrystallinsk cellulose, povidon K30, natriumstivelsesglycolat, lactosemonohydrat, talcum, magnesiumstearat. 
Tablet core: Calcium hydrogen phosphate, Microcrystalline cellulose, Povidone K30, Sodium starch glycollate, Lactose, Talc, Magnesium stearate.
Tag ikke Tasmar: - hvis du har en leversygdom eller forhøjede leverenzymer - hvis du har svære ufrivillige bevægelser (dyskinesier) - hvis du tidligere har haft alvorlige symptomer med muskelstivhed, feber eller mental forvirring (malignt neuroleptikas syndrom (MNS)) og/eller hvis du har haft en speciel form for muskelsygdom med nedbrydning af skeletmuskulaturen (ikke-traumatisk rabdomyolyse) eller feber (hypertermi). 
What you need to know before you take Tasmar Do not take Tasmar: if you have liver disease or increased liver enzymes if you have severe involuntary movement (dyskinesia) if you have a previous history of severe symptoms of muscle stiffening, fever or mental confusion (Neuroleptic Malignant Syndrome (NMS) Symptom Complex ) and /or if you have damage of skeletal muscle tissue (non-traumatic Rhabdomyolysis) or fever (Hyperthermia).
De findes i blisterpakninger på 30 og 60 tabletter og som tabletglaspakninger i pakningsstørrelse på 100 tabletter. 
It is available in blisters in pack sizes of 30 and 60 tablets and in glass bottles in pack sizes of 100 tablets.
Sådan skal du tage Tasmar 
How to take Tasmar
Patienter med nedsat nyrefunktion (se afsnit 5.2) Det anbefales ikke at justere dosis hos patienter med let eller moderat nyreinsufficiens (creatininclearence på 30 ml/min eller højere). 
No dose adjustment of Tasmar is recommended for patients with mild or moderate renal impairment (creatinine clearance of 30 ml/min or greater).
Bemærkning 
Note
Tasmar findes i PVC/PE/PVDC-blisterpakninger (pakningsstørrelser på 30 og 60 filmovertrukne tabletter) og i ravfarvede tabletglas uden tørremiddel (pakningsstørrelse på 30, 60, 100 og 200 filmovertrukne tabletter). 
Tasmar is available in PVC/PE/PVDC blisters (pack sizes of 30 and 60 film-coated tablets) and in amber glass bottles without desiccant (pack sizes of 30, 60,100 and 200 film-coated tablets).
De findes i blisterpakninger på 30 og 60 tabletter og som tabletglaspakninger i pakningsstørrelse på 30, 60, 100 og 200 filmovertrukne tabletter. 
It is available in blisters in pack sizes of 30 and 60 tablets and in glass bottles in pack sizes of 30, 60 ,100 and 200 filmcoated tablets.
behandling med non-selektive monoaminoxidasehæmmere (MAO-hæmmere) fæokromocytom 
Treatment with non-selective mono amino oxidase (MAO) inhibitors
- hvis du tager visse lægemidler til behandling af depression og angst, såkaldte ikke selektive monoaminoxidase hæmmere (MAO) 
if you have a special type of tumor in the adrenal medulla (Phaeochromocytoma) if you take a certain medication to treat depression and anxiety, called non-selective mono amino oxidase (MAO) inhibitors
Tasmar anvendes sammen med lægemidlet levodopa (som levodopa/benserazid eller levodopa/carbidopa). 
For the treatment of Parkinson´s disease, Tasmar is used together with the medicinal product levodopa (as levodopa/benserazide or levodopa/carbidopa).
Danmark Meda A/S Solvang 8 
Danmark Meda A/S
Til behandling af Parkinsons sygdom. 
For the treatment of your Parkinson´s disease you already take levodopa.
Meda Pharma SIA 11018 Tallinn Tel: +372 62 61 025 
11018 Tallinn Tel: +372 62 61 025
For de øvrige patienter faldt transaminaseværdierne til udgangsværdierne efter seponering af behandlingen. 
For the remainder, when treatment was discontinued, transaminase levels returned to pre-treatment levels.
Hjælpestoffer med kendt virkning: Hver tablet indeholder 15 mg lactose Aller hjælpestoffer er anført under pkt. 
Excipients with known effect: Each tablet contains 15 mg lactose For the full list of excipients, see section 6.1.
Sådan tages medicinen 
How to take the medication:
6.1 tegn på leversygdom eller forhøjede leverenzymer svære dyskinesier tidligere malignt neuroleptikasyndrom (MNS) og/eller non-traumatisk rhabdomyolose eller hypertermi. 
Evidence of liver disease or increased liver enzymes Severe dyskinesia A previous history of Neuroleptic Malignant Syndrome (NMS) Symptom Complex and /or non-traumatic Rhabdomyolysis or Hyperthermia.
Forekommer hos flere end 1 ud af 10 behandlede 
may affect more than 1 in 10 people
Du tager allerede levodopa mod Parkinsons sygdom.. Et naturligt protein (enzym) i kroppen (COMT) catechol-O-methyltransferase nedbryder levodopa. 
A natural protein (enzyme) in your body, the (COMT) Catechol-O-methyltransferase breaks down the levodopa.
Tasmar findes som filmovertrukne tabletter indeholdende 200 mg tolcapon. 
Tasmar is supplied as film-coated tablets containing 200 mg tolcapone.
Tasmar findes som filmovertrukne tabletter indeholdende 100 mg tolcapon. 
Tasmar is supplied as film-coated tablets containing 100 mg tolcapone.
Under behandlingen: Under behandlingen skal der tages blodpøver med følgende tidsintervaller: - hver 2. uge i de første 12 behandlingsmåneder - hver 4. uge i de efterfølgende 6 måneder - hver 8. uge derefter Behandlingen vil blive stoppet, hvis blodprøverne bliver unormale. 
While receiving treatment: During treatment, blood tests will be done in the following time intervals: every 2 weeks during the first 12 months of therapy, every 4 weeks during the following 6 months of therapy, every 8 weeks during further treatment.
Du skal så hurtigt som muligt fortælle din læge eller på apoteket: - hvis du føler dig utilpas, mens du tager Tasmar - hvis du får symptomer som f.eks. kvalme, opkastning, mavesmerter, appetitløshed, svaghed, feber, mørkfarvning af urinen eller gulsot (gulfarvning af hud eller øjne), da behandlingen nogle gange kan medføre forstyrrelser i leverfunktionen. 
Tell your doctor or a pharmacist as soon as possible: if you do not feel well while you are taking Tasmar if you experience symptoms such as nausea, vomiting, abdominal pain, loss of appetite, weakness, fever, darkening of urine or jaundice since uncommonly disturbances in the way the liver works, sometimes severe hepatitis was observed, if you notice a darkening of your urine since this could be a sign of a muscular or liver injury.
Natriumstivelsesglycolat Lactosemonohydrat Talcum 
Hydroxypropylmethylcellulose Talc
Filmovertræk: Hypromellose, talcum, gul jernoxid (E 172), ethylcellulose, titandioxid (E 171), triacetin, natriumlaurilsulfat. 
Film-coat: Hydroxypropylmethylcellulose, Talc, Yellow iron oxide, Ethylcellulose, Titanium dioxide, Triacetin, Sodium lauril sulfate.
- Manglende evne til at modstå impulser til at udføre en handling, der kan være skadelig, som for eksempel: o Stærk impuls til at spille overdrevet på trods af personlige eller familiemæssige konsekvenser o Ændret eller øget seksuel interesse og adfærd af væsentlig betydning for dig eller for andre, 
This may include: o Strong impulse to gamble excessively despite serious personal or family consequences.
Sjældne bivirkninger - svær muskelstivhed, feber eller mental forvirring (malignt neuroleptikas syndrom) efter pludselig nedsættelse af dosis af parkinsonmedicin eller pludseligt ophør med parkinsonmedicin. 
severe symptoms of muscle stiffening, fever or mental confusion (Neuroleptic Malignant Syndrome) when antiparkinsonian treatments are abruptly reduced or withdrawn.
Den mest almindelige af disse er øget dyskinesi, kvalme, opkast, abdominal smerter, besvimelsesanfald, ortostatiske klager, forstoppelse, søvnforstyrrelser, somnolens, hallucination. 
The most common of these are increased dyskinesia, nausea, vomiting, abdominal pain, syncope, orthostatic complains, constipation, sleep disorders, somnolence, hallucination.
Leverskade: 
Liver injury:
Fortæl din læge om al receptpligtig og ikke-receptpligtig medicin, du tager. 
Inform your doctor about all prescription and non-prescription medications as the risk of NMS may be increased if you are taking some specific medications.
Almindelige bivirkninger: - brystsmerter - forstoppelse, dyspepsi, mavesmerter, opkastning, tør mund - besvimelse - øget svedtendens - influenzalignende symptomer - ufrivilligt langsomme bevægelser (hypokinesi) - infektion i de øvre luftveje - øgede værdier for specifikke leverenzymer - misfarvning af urinen 
Common: chest pain, constipation, dyspepsia, stomach ache, vomiting, dry mouth, fainting increased sweating, influenza-like symptoms reduced voluntary and involuntary movement (hypokinesia) upper respiratory tract infection increase of specific liver enzymes, urine discoloration
Der forekommer ingen akkumulering af tolcapon ved en dosering på 100 eller 200 mg tre gange daglig. 
Tolcapone does not accumulate with three times daily dosing of 100 or 200 mg. At these doses, Cmax is approximately 3 and 6 µg/ml, respectively.
Disse bivirkninger kan ofte dæmpes ved at reducere dosis af levodopa (se 4.2). 
Reducing the dose of levodopa (see section 4.2) may often mitigate these adverse reactions.
Meget almindelige bivirkninger: - ufrivillige bevægelser (dyskinesi) - kvalme, nedsat appetit, diarre - hovedpine, svimmelhed - søvnproblemer, søvnighed - følelse af svimmelhed, når du står oprejst (ortostatiske symptomer) - forvirring, hallucinationerbevægelsesforstyrrelser og ufrivillige bevægelser (dystoni) - overdrevne drømme 
Very common: involuntary movement (dyskinesia), nausea, decreased appetite, diarrhoea, headache, dizziness sleep problems, somnolence, feeling lightheaded while you stand, (orthostatic complaints),mental confusion and hallucinations, movement disorder with involuntary muscle spasms or malpositions (dystonia), dreaming excessive.
Meget almindelige bivirkninger: - ufrivillige bevægelser (dyskinesi) - kvalme, nedsat appetit, diarre - hovedpine, svimmelhed - søvnproblemer, søvnighed - følelse af svimmelhed, når du står oprejst (ortostatiske symptomer) - forvirring, hallucinationer bevægelsesforstyrrelser og ufrivillige bevægelser (dystoni) 
Very common: involuntary movement (dyskinesia), nausea, decreased appetite, diarrhoea, headache, dizziness sleep problems, somnolence, feeling lightheaded while you stand, (orthostatic complaints), mental confusion and hallucinations, movement disorder with involuntary muscle spasms or malpositions (dystonia).
Forekommer hos mellem 1 og 10 ud af 100 behandlede 
may affect up to 1 in 100 people
Forekommer hos mellem 1 og 10 ud af 1.000 behandlede 
may affect up to 1 in 1,000 people
Følgende frekvenser anvendes for bivirkninger: 
The frequency of possible side effects listed below is defined using the following convention:
Forekommer hos mellem 1 og 10 ud af 10.000 behandlede 
may affect up to 1 in 10,000 people
Justering af levodopa efter seponering af Tasmar 
Levodopa adjustments when Tasmar is discontinued:
Fortæl din læge om al receptpligtig og ikke-receptpligtig medicin du tager. 
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed (non-prescription medicines and herbals).
Tasmar er en orange-gul til brun-gul, ovalformet, filmovertrukken tablet. 
What Tasmar looks like and contents of the pack Tasmar is an orange yellow to brown yellow, oval shaped, film-coated tablet.
Det skal du vide, før du begynder at tage Tasmar Sådan skal du tage Tasmar Bivirkninger 
What Tasmar is and what it is used for What do you need to know before you take Tasmar How to take Tasmar
Hver filmovertrukken tablet indeholder 200 mg tolcapon. 
Each film-coated tablet contains 200 mg tolcapone.
Misfarvet urin 
Urine discoloration
4.3 Kontraindikationer overfølsomhed overfor tolcapon eller over for et eller flere af hjælpestofferne anført i pkt. 
Hypersensitivity to tolcapone or any of its other ingredients listed in section 6.1.
Smerter i brystet 
Chest pain
Hver filmovertrukken tablet indeholder 100 mg tolcapon. 
Each film-coated tablet contains 100 mg tolcapone.
Andre bivirkninger 
Reporting of side effects
Tasmar er en bleg til lys-gul, ovalformet, filmovertrukken tablet. 
What Tasmar looks like and contents of the pack Tasmar is a pale to light yellow, oval shaped, film-coated tablet.
Hver filmovertrukken tablet indeholder 100 mg tolcapon 
Each film-coated tablet contains 100 mg tolcapone
Tasmar 100 mg filmovertrukne tabletter. 
Tasmar 100 mg film-coated tablets
Ortostatiske symptomer 
Hepatobiliary disorders
Opbevar Tasmar utilgængeligt for børn. 
How to store Tasmar Keep out of the sight and reach of children.
Tasmar 100 mg filmovertrukne tabletter Tolcapon 
Tasmar 100 mg film-coated tablets Tolcapone
Tasmar 200 mg filmovertrukne tabletter Tolcapon 
Tasmar 200 mg film-coated tablets Tolcapone
Hvis du har taget for mange Tasmar 
If you take more Tasmar than you should
- Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide. 
You should check with your doctor or pharmacist if you are unsure.
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din læge eller apoteket til råds, før du tager Tasmar. 
- if you are pregnant or intend to become pregnant.
Hver filmovertrukken tablet indeholder 200 mg tolcapon 
Each film-coated tablet contains 200 mg tolcapone tolcapone 200 mg
Tasmar indeholder laktose Kontakt lægen før du tager Tasmar, hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter. 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Tasmar 200 mg filmovertrukne tabletter. 
Tasmar 200 mg film coated tablets
- Lægen har ordineret Tasmar til dig personligt. 
This medicine has been prescribed for you.
Svimmelhed Somnolens 
Dyskinesia Dystonia Headache Dizziness
- hvis du tager visse lægemidler til behandling af depression og angst, såkaldte ikke- selektive monoaminoxidase hæmmere (MAO) - Hvis du er gravid eller planlægger at blive gravid. 
if you have a special type of tumor in the adrenal medulla (Phaeochromocytoma) - if you take a certain medication to treat depression and anxiety, called non-selective mono amino oxidase (MAO) inhibitors
Meget almindelig (>1/10) almindelig (>1/100, <1/10) ikke almindelig (>1/1000, <1/100) sjælden (>1/10.000, <1/1000) meget sjælden (<1/10.000), ikke kendt (kan ikke estimeres ud fra tilgængelige data) 
Rare (≥1/10,000 to < 1/1,000)
Hypromellose Talcum 
Titanium dioxide Triacetin
Dette er med til at beskytte mod sygdommene. 
This will help to protect against the diseases.
Hævelsen forsvinder fuldstændigt ved slutningen af den tredje uge. 
The swelling will resolve completely by the end of the third week.
Dette sammendrag blev sidst ajourført den 07/09/2011. 
This summary was last updated on 7 September 2011.
Der kan forekomme en forbigående stigning i legemstemperaturen på 1-2 °C. 
A temporary increase in body temperature of 1-2°C can occur.
Der kan ligeledes forekomme en lille, smertefri hævelse på injektionsstedet i løbet af de første to uger efter vaccinationen. 
There may also be a small, painless swelling at the injection site within the first two weeks after vaccination.
E-mail info@ema.europa.eu Website www.em .europa.eu 
E-mail info@ema.europa.eu Website www.ema.europa.eu
Hvis kaninerne senere udsættes for nogen af viraene, vil immunsystemet hurtigere kunne reagere. 
In the future, if the rabbits are exposed to any of the viruses, the immune system will be able to respond more quickly.
Det fås som et lyofilisat (et frysetørret stof) og en solvens, der anvendes til at fremstille en injektionsvæske, suspension. 
It is available as a lyophilisate (freeze-dried substance) and a solvent that are made up into a suspension for injection.
Det indeholder en svækket stamme af myxomavirus, der er blevet genetisk modificeret, så den kan danne et protein i RHD-virussen. 
It contains a weakened strain of the myxoma virus which has been genetically modified so that it can produce a protein of the RHD virus.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Nobivac Myxo-RHD til Intervet International BV den 07/09/2011. 
The European Commission granted a marketing authorisation valid throughout the European Union, for Nobivac Myxo-RHD to Intervet International BV on 7 September 2011.
Undersøgelserne viste, at Nobivac Myxo-RHD var effektivt til at give immunitet mod myxomatose og RHD tre uger efter vaccinationen, og at der stadig var immunitet efter et år. 
The studies showed that Nobivac Myxo-RHD was effective in providing immunity against myxomatosis and RHD three weeks after vaccination and that the immunty was still present after one year.
Ligesom alle andre vacciner virker Nobivac Myxo-RHD ved at "lære" immunsystemet (kroppens naturlige forsvar), hvordan det skal beskytte sig mod en sygdom. 
Nobivac Myxo-RHD, like all vaccines, works by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
Når vaccinen gives til kaniner, opfatter deres immunsystem myxoma- og RHD-materialerne som "fremmede" og reagerer ved at danne antistoffer imod dem. 
When it is given to rabbits the immune system recognises the myxoma and RHD materials as ‘foreign' and makes antibodies against them.
Der blev foretaget 15 felt- og laboratorieundersøgelser, hvor kaniner vaccineret med Nobivac MyxoRHD blev sammenlignet med ikke-vaccinerede kaniner for at fastlægge start og varighed af immunitet mod myxoma- og RHD-vira. 
Fifteen field and laboratory studies were carried out, in which rabbits vaccinated with Nobivac MyxoRHD were compared with unvaccinated rabbits to establish the onset and duration of immunity against myxoma and RHD viruses.
Nobivac Myxo-RHD er en vaccine, der indeholder levende myxoma vector RHD virus stamme 009. 
Nobivac Myxo-RHD is a vaccine that contains live myxoma vectored RHD virus strain 009.
Levende myxoma vector RHD virus stamme 009 
Live myxoma vectored RHD virus strain 009
Kaniner, som blev vaccineret med Nobivac Myxo-RHD, havde færre tegn på myxomatose, flere antistoffer mod RHD-virus i blodet og en lavere dødelighed end ikke-vaccinerede kaniner. 
Rabbits that were vaccinated with Nobivac Myxo-RHD had fewer signs of myxomatosis, more antibodies against RHD virus in their blood and a lower death rate than unvaccinated rabbits.
Nobivac Myxo-RHD anvendes til kaniner fra 5-ugers alderen for at nedsætte dødeligheden og de kliniske symptomer ved myxomatose (hudkræft, der skyldes myxomavirus) og for at forebygge dødeligheden ved Rabbit Heamorrhagic Disease (RHD), som er en sygdom, der resulterer i blodpropdannelse som følge af RHD-virus. 
Nobivac Myxo-RHD is used in rabbits aged five weeks or more to reduce number of deaths and clinical signs due to myxomatosis (skin tumours caused by the myxoma virus) and to prevent death due to rabbit haemorrhagic disease (RHD), a disease resulting in blood clot formation caused by the RHD virus.
Udvalget for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved Nobivac Myxo-RHD opvejer risiciene, når det anvendes til at nedsætte dødeligheden og de kliniske symptomer ved myxomatose og forebygge dødeligheden ved Rabbit Heamorrhagic Disease. 
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Nobivac Myxo-RHD exceed the risks when used to reduce the number of deaths and clinical signs due to myxomatosis and prevent death due to rabbit haemorrhagic disease.
Tilbageholdelsestiden for Nobivac Myxo-RHD er nul dage. 
The withdrawal period for Nobivac Myxo-RHD is zero days.
Andre oplysninger om Nobivac Myxo-RHD: 
Other information about Nobivac Myxo-RHD:
Udvalget anbefalede udstedelse af en markedsføringstilladelse for Nobivac Myxo-RHD. 
The Committee recommended that Nobivac Myxo-RHD be given a marketing authorisation.
Hvilken risiko er der forbundet med Nobivac Myxo-RHD? 
What is the risk associated with Nobivac Myxo-RHD?
Hvorfor blev Nobivac Myxo-RHD godkendt? 
Why has Nobivac Myxo-RHD been approved?
Hvad er Nobivac Myxo-RHD? 
What is Nobivac Myxo-RHD?
Hvordan blev Nobivac Myxo-RHD undersøgt? 
How has Nobivac Myxo-RHD been studied?
Hvad anvendes Nobivac Myxo-RHD til? 
What is Nobivac Myxo-RHD used for?
Hvordan virker Nobivac Myxo-RHD? 
How does Nobivac Myxo-RHD work?
Hvilken fordel viser undersøgelserne, at der er ved Nobivac Myxo-RHD? 
What benefit has Nobivac Myxo-RHD shown during the studies?
<særnavn> er kontraindikeret i følgende situationer: 
<Invented name> is contraindicated in the following situations:
Den daglige dosis bør fordeles på mindst to enkeltdoser. 
The daily dose should be divided into at least two single doses.
Der er begrænsede data for langtidsvirkninger. 
There are limited data on the long term outcomes.
Jo højere dosis, jo højere risici, men alle doser indebærer en risiko. 
The higher the dose, the higher the risks but all doses carry a risk.
Dette er en højere risiko for alvorlige misdannelser end i den almindelige befolkning, hvor risikoen er ca. 2-3 %. 
This is a greater risk of major malformations than for the general population, for whom the risk is about 2-3%.
• Nødvendigheden af regelmæssig gennemgang af behandlingen. 
• The need for regular review of treatment.
Den ordinerende læge skal især sikre, at patienten forstår: 
In particular the prescriber must ensure the patient understands:
Lægen vil stoppe din behandling og give dig yderligere rådgivning. 
Your doctor will stop your treatment and advise you further.
Produktinformationen kan efterfølgende opdateres af den relevante myndighed i medlemslandet, i samarbejde med referencemedlemslandet efter behov, i overensstemmelse med procedurerne som er beskrevet i kapitel 4 titel III i direktiv 2001/83/EC. 
The product information may be subsequently updated by the Member State competent authorities, in liaison with the Reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC.
Afibrinogenæmi er også blevet rapporteret og kan være dødelig. 
Afibrinogenemia has also been reported and may be fatal.
FØRSTE RECEPT 
FIRST PRESCRIPTION
Dette kan sammenlignes med 2-3 babyer ud af 100 født af kvinder, der ikke har epilepsi. 
This compares to 2-3 babies in ever 100 born to women who don't have epilepsy.
Valproat udskilles i human mælk med en koncentration mellem 1 % og 10 % af moderens serumniveau. 
Valproate is excreted in human milk with a concentration ranging from 1% to 10% of maternal serum levels.
Den nøjagtige gestationale risikoperiode for disse effekter er usikker, og muligheden for risiko under hele graviditeten kan ikke udelukkes. 
The exact gestational period of risk for these effects is uncertain and the possibility of a risk throughout the entire pregnancy cannot be excluded.
Da valproat har været brugt i mange år, ved vi, at hos kvinder, der tager valproat, vil omkring 10 babyer ud af 100 have misdannelser. 
Because valproate has been used for many years we know that in women who take valproate around 10 babies in every 100 will have birth defects.
• Arten og omfanget af risici ved eksponering under graviditet, især de teratogene risici og risikoen for udviklingsmæssige forstyrrelser. 
• The nature and the magnitude of the risks of exposure during pregnancy, in particular the teratogenic risks and the risks of developmental disorders.
• Det skønnes, at op til 30-40 % af førskolebørn, hvis mødre har taget valproat under graviditeten, kan have problemer med den tidlige udvikling. 
• It is estimated that up to 30-40% of preschool children whose mothers took valproate during pregnancy may have problems with early childhood development.